23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki

Core Viewpoint - The Special Committee of 23andMe has received a non-binding acquisition proposal from CEO Anne Wojcicki to buy out all outstanding shares not owned by her or her affiliates for $0.41 per share, which is an 84$2.53 per share [1][2]. Group 1 - The acquisition proposal was confirmed in an amended Schedule 13D filing with the SEC [1]. - The Special Committee has unanimously rejected the acquisition proposal after consulting with financial and legal advisors [2]. - Moelis & Company LLC is acting as the financial advisor and Goodwin Procter LLP as the legal advisor to the Special Committee [2]. Group 2 - 23andMe is a genetics-led consumer healthcare and biopharmaceutical company focused on empowering a healthier future [3].